Advertisement

Picture BIO Deutschland German Corona Special 2021 Digital 650x80px
Organisation › Details

Vaxxel S.A.S.

Vaxxel is a start-up from Virpath, the virology and human pathology of the University Claude Bernard in Lyon (UCBL), France, and has been founded by Dr. Manuel Rosa-Calatrava Co-Director of Virpath (Lyon), by Pr. Guy Boivin of the University of Laval (Quebec), and by Denis Cavert, President of Vaxxel. Vaxxel develops live-attenuated vaccines against Metapneumovirus and against the Respiratory Syncytial Virus based on the Metavac® vaccine platform. This platform has been funded and licensed by Pulsalys and supported by Lyon Ingénierie Projets (LIP), a subsidiary of UCBL. Proof of Concept of the first monovalent vaccine candidate against the Metapneumovirus has been demonstrated on both animal and human ex vivo models. The company is a recipient of the 2019 i-Lab award, organized by the Ministry of Higher Education, Research and Innovation in partnership with Bpifrance, and has also received “FrenchTech seed” label. About Vaxxel vaccine candidates Vaxxel develops two vaccine candidates against respiratory infections: a monovalent vaccine against human Metapneumovirus (hMPV), and a bivalent vaccine against both hMPV and Respiratory Syncytial Virus (hRSV). These two viruses are the source of acute respiratory infections such as pneumonia or bronchiolitis in children below 5 years old and in older adults above 65 years old. They can lead to patient hospitalization, and even cause their death. Today, there is no vaccine available to protect the 195 million persons at risk (including 46 million children) from these severe infections (US and EU, 2018). Vaxxel’s live attenuated vaccine candidates are based on two proprietary technologies: Metavac®, an hMPV seed attenuated through reverse genetic, and DuckCelt®-T17, an avian cell line ge-ronw in suspension with demonstrated capability to be used at industrial scale. The objective of Vaxxel’s technology is to mimic natural infection without causing the disease and to activate both humoral and mucosal immunity. *

 

Period Start 2019-09-23 established (s-off
Products Industry Metavac® vaccine platform
  Industry 2 DuckCelt®-T17 cell line
Person Person Cavert, Denis (Vaxxel 202004 President + Co-Founder)
     
Region Region Villeurbanne
  Country France
  Street 43 boulevard du Onze Novembre 1918
  City 69100 Villeurbanne
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Transgene S.A.. (5/4/20). "Press Release: Vaxxel Acquires Transgene’s DuckCelt-T17 Cell Line to Develop Industrial-scale Vaccines against Respiratory Viruses". Lyon & Strasbourg.
     
   
Record changed: 2020-08-04

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Vaxxel S.A.S.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Back into Ad 650x80px




» top